Search Results

Armed with the latest biological knowledge and cutting-edge computational techniques—and, of course, investor dollars—these six biotechs are playing in the largely underappreciated longevity space, developing therapies that may improve the quality of aging.

The industry sector focused on aging is only about 10 years old, but acting on what scientists already know, a new crop of biotechs, backed by investors, are taking a disease-centric approach to extending the human lifespan.

Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.

The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in aging-related diseases. Chugai will then develop antibody-based drugs based on the findings.

NSG BioLabs announces a new partnership with Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world, to support biotech startups by providing needed resources such as product and applications expertise and its networks to advance startup research and development.